Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Registrati

Quotazioni in diretta

IMAB I MAB

1,09

0,00 (0,00%)

Pre Mercato

Ultimo aggiornamento: 11:24:40

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

3 C BASED ON ADS 3 D BASED ON CLOSING PRICE 1.63 JULY 16 3 E BASED ON ORDINARY SHARES UNDER SECURITIES TO BE SOLD DATE AND NATURE OF PAYMENT NA

Date of Notice

07/17/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

CONFORMED SIGNATURE ON FILE

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni I MAB (NASDAQ:IMAB)
Storico
Da Dic 2024 a Gen 2025

Clicca qui per i Grafici di I MAB

Grafico Azioni I MAB (NASDAQ:IMAB)
Storico
Da Gen 2024 a Gen 2025

Clicca qui per i Grafici di I MAB

Notizie I MAB - IMAB

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunedì 13 Gennaio 2025 (1 settimana fa) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercoledì 8 Gennaio 2025 (2 settimane fa) • Edgar (US Regulatory)

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Mercoledì 8 Gennaio 2025 (2 settimane fa) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunedì 6 Gennaio 2025 (2 settimane fa) • Edgar (US Regulatory)

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Lunedì 6 Gennaio 2025 (2 settimane fa) • PR Newswire (US)

I-Mab to Participate at the Piper Sandler Healthcare Conference
Giovedì 21 Novembre 2024 (2 mesi fa) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Giovedì 14 Novembre 2024 (2 mesi fa) • Edgar (US Regulatory)

I-Mab Reports Third Quarter 2024 Results
Giovedì 14 Novembre 2024 (2 mesi fa) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mercoledì 6 Novembre 2024 (3 mesi fa) • Edgar (US Regulatory)

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
Mercoledì 6 Novembre 2024 (3 mesi fa) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martedì 5 Novembre 2024 (3 mesi fa) • Edgar (US Regulatory)

I-Mab to Release Q3 2024 Financial Results on November 14, 2024
Giovedì 31 Ottobre 2024 (3 mesi fa) • PR Newswire (US)

Più I MAB Articoli Notizie

BNP Paribas Issuance

Harmony Gold Mining

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea